NIH activates new funding vehicle for COVID-19 R&D, other measures seek more information
For the first time and in response to the COVID-19 outbreak, the National Institute of Allergy and Infectious Diseases (NIAID) together with the National Institute of General Medical Sciences (NIGMS) has activated the NIH Urgent Award mechanism. The targeted opportunity is intended to provide funds for NIH grantees applying to expand the scope of their active grant.
Would an increase in the quantity of NIH SBIR awards impact their overall quality?
In a recent study titled Does NIH select the right healthcare ventures through the SBIR grant program?, researchers from Rutgers University and the University of Connecticut took advantage of the 2009 American Recovery and Reinvestment Act (ARRA) to conduct a natural experiment.
In a recent study titled Does NIH select the right healthcare ventures through the SBIR grant program?, researchers from Rutgers University and the University of Connecticut took advantage of the 2009 American Recovery and Reinvestment Act (ARRA) to conduct a natural experiment. The opportunity was available due to the National Institutes of Health (NIH) decision to use ARRA dollars to fund additional Phase I SBIR awards from general SBIR competitions, and the researchers compared these 19 ARRA-funded awards to the other 479 Phase I awards that were first funded in the same competitions with regular appropriations.
NIH posts modifications to proposal application and review process
How one applies and has their proposal reviewed to gain a small share of the world's largest funding source for life science research is changing. The following highlights modifications affecting grant applications submitted to the National Institutes of Health for due dates on or after January 25, 2025, as posted on their Implementation of New Initiatives and Policies page.